Literature DB >> 12008785

Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia.

Christopher S Alexander1, Valentina Montessori, Brian Wynhoven, Winnie Dong, Keith Chan, Michael V O'Shaughnessy, Theresa Mo, Magda Piaseczny, Julio S G Montaner, P Richard Harrigan.   

Abstract

In North America, the B subtype of the major group (M) of HIV-1 predominates. Phylogenetic analysis of HIV reverse transcriptase and protease sequences isolated from 479 therapy-naive patients, first seeking treatment in British Columbia between June 1997 and August 1998, revealed a prevalence of 4.4% non-B virus. A range of different subtypes was identified, including one subtype A, 11 C, two D, five CRF01_AE, and one sample that could not be reliably subtyped. Baseline CD4 courts were significantly lower in individuals harbouring the non-B subtypes (P = 0.02), but baseline viral loads were similar (P = 0.80). In this study, individuals infected with non-B variants did not have a significantly different virological response to therapy after up to 18 months.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12008785

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  16 in total

Review 1.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

Review 2.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

3.  Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.

Authors:  Ming-Tain Lai; Meiqing Lu; Peter J Felock; Renee C Hrin; Ying-Jie Wang; Youwei Yan; Sanjeev Munshi; Georgia B McGaughey; Robert M Tynebor; Thomas J Tucker; Theresa M Williams; Jay A Grobler; Daria J Hazuda; Philip M McKenna; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

4.  Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.

Authors:  Krista A Delviks-Frankenberry; Renan B Lengruber; Andre F Santos; Jussara M Silveira; Marcelo A Soares; Mary F Kearney; Frank Maldarelli; Vinay K Pathak
Journal:  Virology       Date:  2012-10-13       Impact factor: 3.616

5.  Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.

Authors:  Dan Turner; Bluma Brenner; Daniela Moisi; Mervi Detorio; Raymond Cesaire; Takashi Kurimura; Haruyo Mori; Max Essex; Shlomo Maayan; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

6.  HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.

Authors:  Bohdan Nosyk; Jeong Min; Viviane D Lima; Benita Yip; Robert S Hogg; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

7.  Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.

Authors:  Evan T Brower; Arne Schön; Ernesto Freire
Journal:  Biochemistry       Date:  2010-03-23       Impact factor: 3.162

Review 8.  Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease.

Authors:  Kevin J Liner; Colin D Hall; Kevin R Robertson
Journal:  J Neurovirol       Date:  2007-08       Impact factor: 2.643

9.  Characterizing Human Immunodeficiency Virus Antiretroviral Therapy Interruption and Resulting Disease Progression Using Population-Level Data in British Columbia, 1996-2015.

Authors:  Linwei Wang; Jeong Eun Min; Xiao Zang; Paul Sereda; Richard P Harrigan; Julio S G Montaner; Bohdan Nosyk
Journal:  Clin Infect Dis       Date:  2017-10-16       Impact factor: 9.079

10.  HIV Genetic Diversity and Drug Resistance.

Authors:  André F Santos; Marcelo A Soares
Journal:  Viruses       Date:  2010-02-02       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.